Who is sponsoring NCT00079092?

NCT00079092 is sponsored by Wake Forest University Health Sciences.

What drugs are being tested in NCT00079092?

Interventions in NCT00079092: procarbazine hydrochloride, thalidomide.

What condition does NCT00079092 study?

NCT00079092 studies Brain and Central Nervous System Tumors.

Is NCT00079092 still recruiting?

NCT00079092 is currently completed. Last updated 9 September 2021.

Last reviewed 2021-09-09 · How we verify

NCT00079092

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Thalidomide and Procarbazine in Treating Patients With Recurrent or Progressive Malignant Glioma

Completed Phase 2 Last updated 9 September 2021

What this trial tests

Phase 2 trial testing procarbazine hydrochloride in Brain and Central Nervous System Tumors in 18 participants. Completed in 21 March 2006.

Timeline

1 January 2004

Primary endpoint
21 March 2006

21 March 2006

Quick facts

Lead sponsor	Wake Forest University Health Sciences
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Masking	none
Primary purpose	treatment
Enrollment	18
Start date	1 January 2004
Primary completion	21 March 2006
Estimated completion	21 March 2006
Sites	5 locations across United States

Drugs / interventions tested

procarbazine hydrochloride — full drug profile →
thalidomide (THALIDOMIDE) — full drug profile →

Conditions studied

Brain and Central Nervous System Tumors — all drugs for Brain and Central Nervous System Tumors →

Sponsor

Wake Forest University Health Sciences

Who can join

Adults 18 to 120, any sex, with Brain and Central Nervous System Tumors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

RATIONALE: Thalidomide may stop the growth of malignant glioma by stopping blood flow to the tumor. Drugs used in chemotherapy, such as procarbazine, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining thalidomide with procarbazine may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving thalidomide together with procarbazine works in treating patients with recurrent or progressive malignant glioma.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Neuroinflammation as a Factor of Neurodegenerative Disease: Thalidomide Analogs as Treatments.
Jung YJ, Tweedie D, Scerba MT, Greig NH. · · 2019 · cited 116× · PMID 31867326 · DOI 10.3389/fcell.2019.00313
A Systematic Review of Glioblastoma-Targeted Therapies in Phases II, III, IV Clinical Trials.
Cruz Da Silva E, Mercier MC, Etienne-Selloum N, Dontenwill M, et al · · 2021 · cited 99× · PMID 33918704 · DOI 10.3390/cancers13081795

Verify or expand the search:

Other trials of procarbazine hydrochloride

Trials testing the same drug.

NCT01775475 — Intravenous Chemotherapy or Oral Chemotherapy in Treating Patients With Previously Untreated Stage III-IV HIV-Associated · Phase 2 · completed
NCT00678327 — Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Sta · Phase 3 · completed
NCT00574496 — Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary · Phase 2 · completed
NCT00379041 — Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Previously Untreated Stage I or Sta · Phase 3 · active not recruiting

Other recruiting trials for Brain and Central Nervous System Tumors

Currently open trials in the same condition.

NCT00978458 — Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma · Phase 3 · active not recruiting

Other Wake Forest University Health Sciences trials

Trials by the same sponsor.

NCT07474090 — Personalized Exercise Program for Survivors of Breast Cancer, STEPS-BC Trial · NA · not yet recruiting
NCT07282444 — A New Way to Share Radiation Therapy Plans Between Doctors, CORRECT Trial · NA · not yet recruiting
NCT06876896 — Intra-abdominal Pressure (IAP) During PFA Treatment of A-fib/ A-Flutter · NA · recruiting
NCT07227051 — Optimizing Self-Monitoring Feedback Delivery for the Treatment of Overweight and Obesity · NA · recruiting
NCT07215624 — Surgical Thromboprophylaxis Practices in Oncology Patients Within the NCORP Network, STOP-VTE Study · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00079092 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Wake Forest University Health Sciences
Last refreshed: 9 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00079092.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing